trial summary

Cardiovascular prevention

All chronical situations: 6 trials - Marmorstein - Stamler - VA Neurology Section (estrogen) - CDP estrogen 5 - CDP estrogen 2.5 - VA drugs (Estrogen or thyroxine)

No demonstrated result

No demonstrated result

suggested Coronary death by 67% (not demonstrated)

suggested All cause death by 61% (not demonstrated)

suggested non cardiovascular death by 57% (not demonstrated)

See more clinical conditions

All type of patients: 17 trials - ERA (estrogen alone ) - WAVE - WELL-HART (estrogen alone) - Schulman (NHLBI) (estrogen alone) - EAGAR - HERS - EPAT - EVTET - Hall - ESPRIT - WEST - WHI - WHISP - WISDOM - ERA (estrogen plus medroxyprogesterone) - WELL-HART (estrogen-progestin) - Schulman (NHLBI) (estrogen-progestogen)

No demonstrated result

suggested puylmonary embolism by 135% (not demonstrated)

suggested Venous thromboembolism by 262% (not demonstrated)

suggested stroke (fatal and non fatal) by 24% (not demonstrated)

No demonstrated result

Patients with other atherosclerotic localisation: 1 trials - VA Neurology Section (estrogen)

No demonstrated result

Patients with prior MI or with CHD: 5 trials - Marmorstein - Stamler - CDP estrogen 5 - CDP estrogen 2.5 - VA drugs (Estrogen or thyroxine)

No demonstrated result

No demonstrated result

suggested Coronary death by 67% (not demonstrated)

suggested All cause death by 61% (not demonstrated)

suggested non cardiovascular death by 57% (not demonstrated)

Primary prevention: 2 trials - EPAT - WHI

No demonstrated result

suggested puylmonary embolism by 115% (not demonstrated)

suggested Venous thromboembolism by 115% (not demonstrated)

suggested cardiovascular events by 19% (not demonstrated)

suggested stroke (fatal and non fatal) by 42% (not demonstrated)

suggested Coronary event by 28% (not demonstrated)

suggested Non fatal MI by 32% (not demonstrated)

No demonstrated result

Secondary prevention: 13 trials - ERA (estrogen alone ) - WAVE - WELL-HART (estrogen alone) - Schulman (NHLBI) (estrogen alone) - EAGAR - HERS - EVTET - Hall - ESPRIT - WHISP - ERA (estrogen plus medroxyprogesterone) - WELL-HART (estrogen-progestin) - Schulman (NHLBI) (estrogen-progestogen)

No demonstrated result

suggested Venous thromboembolism by 1372% (not demonstrated)

No demonstrated result